AEZS - Aeterna Zentaris Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

Aeterna Zentaris Inc.

315 Sigma Drive
Suite 302D
Summerville, SC 29483
United States

Full Time Employees

Key Executives

Dr. Richard Sachse M.D., Ph.D.Sr. VP, CSO & Chief Medical Officer277.5kN/AN/A
Mr. Michael V. WardChief Exec. OfficerN/AN/A60
Mr. Paul BurroughsDirector of CommunicationsN/AN/AN/A
Dr. Eckhard G. Guenther Ph.D.VP of Alliance ManagementN/AN/AN/A
Dr. Michael Teifel Ph.D.VP of Non-Clinical SciencesN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The company’s product pipeline includes Zoptrex, which completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer, as well as in various phases for the treatment of ovarian and prostate cancer; and MACRILEN, which completed Phase III trial for use in the diagnosis of adult growth hormone deficiency. It is also developing an LHRH-disorazol Z conjugate, which is in pre-clinical development in oncology. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Summerville, South Carolina.

Corporate Governance

Aeterna Zentaris Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.